Compare DexCom, Inc. (DXCM) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Gartner Inc — how do they compare? DexCom, Inc. trades at $77.41 (market cap $28.06B), while Gartner Inc trades at $137.68 (market cap $8.96B). The key difference: DexCom, Inc. is far larger — about 3.1× Gartner Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | IT | |
|---|---|---|
Market Cap | $28.06B | $8.96B |
Sector | Health | Technology |
52-Week High | $89.53 | $363.58 |
52-Week Low | $54.84 | $125.68 |
Enterprise Value | $27.03B | $10.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Gartner (IT) trades at $136.24, up 2.46% today, with a bearish technical signal but strong fundamentals including a 13.22 P/E ratio and consistent earnings beats. Revenue grew to $6.5B in 2025, though net income fell to $729M. Recent news highlights ongoing legal investigations and the company's influential role in tech research, with multiple firms named in Gartner reports.
The stock presents a mixed outlook: valuation metrics are attractive and analyst consensus targets $157.60, but technical weakness and legal overhangs pose near-term risks. Earnings momentum remains a key catalyst, though investor sentiment is cautious amid competition and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
